

## **ESC Declaration of Interests Report**

### **2024 ESC Guidelines for the management of atrial fibrillation**

The ESC reviews relationships with healthcare industry and encourages transparency and ethical integrity.

It is mandatory for all experts involved in the development of ESC Guidelines to comply with the ESC Declaration and Management of Conflict of Interest Policy. Under this policy, they are required to submit a yearly Declaration of Interests (DOI) during the writing and reviewing phases of the Guidelines.

All DOIs presented in this report were assessed prior to work commencing and during the development of the Guidelines, according to the applicable review criteria in place at the time and as defined in the ESC Declaration and Management of Conflict of Interest Policy, Annex 3.

The most up-to-date version of the policy and its annexes are available on the ESC website at [www.escardio.org/DOI](http://www.escardio.org/DOI).

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Bunting Karina V	<p><b>2021</b>     <b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b>            Awarded a Career Development Fellowship from the British Heart Foundation (FS/CDRF/21/21032) Awarded a grant from the University of Birmingham's British Heart Foundation Accelerator Award (BHF AA/18/2/34218) Committee member for the British Society of Echocardiography Clinical Standards and Education Committee</p>
	<p><b>2022</b>     <b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b>            Career Development Fellowship from the British Heart Foundation (FS/CDRF/21/21032) PhD funded through the RATE-AF trial's Career Development grant awarded to Prof Dipak Kotecha: National Institute for Health Research UK – CDF-2015-08-074 and HTA-130280 Awarded a grant from the University of Birmingham's British Heart Foundation Accelerator Award (BHF AA/18/2/34218) Committee member for the British Society of Echocardiography's Clinical Standards and Education Committee</p>
	<p><b>2023</b>     <b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b>            British Heart Foundation</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b>            Career Development Fellowship from the British Heart Foundation (FS/CDRF/21/21032) PhD funded through the RATE-AF trial's Career Development grant awarded to Prof Dipak Kotecha: National Institute for Health Research UK – CDF-2015-08-074 and HTA-130280 Awarded a grant from the University of Birmingham's British Heart Foundation Accelerator Award (BHF AA/18/2/34218) Committee member for the British Society of Echocardiography's Clinical Standards and Education Committee</p>
Casado Arroyo Ruben	<p><b>2021</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            St Jude Medical : speaker educational fees            Johnson &amp; Johnson : speaker educational fees</p>
	<p><b>2022</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Abbott : Arrhythmias, General            Boston Scientific : Arrhythmias, General</p>
	<p><b>2023</b>     <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            Abbott : Training and Education</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Caso Valeria	<p><b>2021</b>     <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Daiichi Sankyo : af and stroke prevention  Bayer AG : factor XI research  Boehringer-Ingelheim : stroke</p>
	<p><b>2022</b>     <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Bayer : Atrial Fibrillation (AF)  Boehringer-Ingelheim : Stroke, Other</p>
	<p><b>2023</b>     <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>  Pfizer : Atrial Fibrillation (AF)  EVER Neuro Pharma : Stroke</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b>  Bayer AG : CHAIR OF THE OCEANIC AF TRIAL , CO-CHAIR OF THE OCEANIC AF  Boehringer-Ingelheim : RESEARCH ON THE APPLICATION OF AI IN STROKE RECOGNITION , PRINCIPAL INVESTIGATOR</p>
Crijns Harry	<p><b>2021</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Sanofi Aventis : Antiarrhythmic drug  Daiichi Sankyo : Anticoagulation  Roche Diagnostics : Biomarkers</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Cardialysis : Adjudication committee  InCarda Therapeutics : Antiarrhythmic agent  Corsano Health : Rhythm monitoring device</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Crijns Harry	<b>2021</b> <b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> Netherlands Heart Foundation
	<b>2022</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Daiichi Sankyo : Atrial Fibrillation (AF) Sanofi Aventis : Atrial Fibrillation (AF) Roche Diagnostics : Atrial Fibrillation (AF) Acesion Pharma : Atrial Fibrillation (AF), Pharmacology and Pharmacotherapy <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> InCarda Therapeutics : Atrial Fibrillation (AF) Cardialysis : Atrial Fibrillation (AF), Pharmacology and Pharmacotherapy Corsano Health : e-Cardiology/Digital Health

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Crijns Harry	<p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b>  DZHK  ZonMW</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>  Daiichi Sankyo : Atrial Fibrillation (AF)  Sanofi Aventis : Atrial Fibrillation (AF)  Roche Diagnostics : Atrial Fibrillation (AF)  Acesion Pharma : Atrial Fibrillation (AF), Pharmacology and Pharmacotherapy</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>  Medtronic : Atrial Fibrillation (AF)  Atricure : Atrial Fibrillation (AF)  InCarda Therapeutics : Atrial Fibrillation (AF)  Cardialysis : Atrial Fibrillation (AF), Pharmacology and Pharmacotherapy</p>
De Potter Tom	<p><b>2021</b></p> <p>Nothing to be declared</p> <hr/> <p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Boston Scientific : Atrial Fibrillation (AF)  Biosense Webster : Atrial Fibrillation (AF)  Adagio Medical : Atrial Fibrillation (AF), Ventricular Arrhythmias and Sudden Cardiac Death (SCD)  Abbott Vascular : Other</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>  Abbott Vascular : Vascular closure device feasibility study in PVI, PI</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
De Potter Tom	<p><b>2022</b></p> <p><b>Direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</b> Healthcare - Ventricular Arrhythmias and Sudden Cardiac Death (SCD) - Stock options, Adagio Medical. Less than 10k euro.</p>
	<p><b>2023</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Boston Scientific : Atrial Fibrillation (AF) Biosense Webster : Atrial Fibrillation (AF) Adagio Medical : Atrial Fibrillation (AF), Ventricular Arrhythmias and Sudden Cardiac Death (SCD) Abbott Vascular : Other</p> <p><b>Direct financial interest in healthcare, media, education companies, or in companies related to or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</b> Healthcare - Ventricular Arrhythmias and Sudden Cardiac Death (SCD) - Stock options, Adagio Medical. Less than 10k euro.</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b> Associate editor for Journal of Interventional Cardiac Electrophysiology</p>
Dwight Jeremy	<p><b>2021</b></p> <p><b>Receipt of royalties for intellectual property.</b> Oxford University Press : Cardiovascular medicine</p> <p><b>Employment in healthcare industry (including part time) during the year for which you are declaring.</b> PassPACES. Education course for candidates for the examination of Membership of the Royal College of Physicians.</p>
	<p><b>2022</b></p> <p><b>Receipt of royalties for intellectual property.</b> Oxford University Press : Other</p>
	<p><b>2023</b></p> <p><b>Receipt of royalties for intellectual property.</b> Oxford University Press : Other</p>
Guasti Luigina	<p><b>2021</b></p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Sanofi Aventis : cardiovascular prevention</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Guasti Luigina	<b>2022</b> <b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Sanofi Aventis : education / organization of local educational activities, organization of edu activities
	<b>2023</b> <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Sanofi Aventis : Risk Factors and Prevention
Hanke Thorsten	<b>2021</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Atricure : Atrial fibrillation Management and LAA management Bioventrix : Heart Failure treatment
	<b>2022</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Atricure : Atrial Fibrillation (AF) Edwards Lifesciences : Valvular Heart Disease
	<b>2023</b> <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Atricure : Atrial Fibrillation (AF)
Jaarsma Tiny	<b>2021</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Boehringer-Ingelheim : heart failure
	<b>2022</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Boehringer-Ingelheim : History of Cardiology, Cardiovascular Nursing and Allied Professions
	<b>2023</b> <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Boehringer-Ingelheim : History of Cardiology, Cardiovascular Nursing and Allied Professions

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Kotecha Dipak	<p><b>2021</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer : Data Science (Advisory Board)            Amomed : Data Science (Advisory Board)            Protherics Medicines Development : Data Science (Advisory Board)            MyoKardia : Trial Advisory Board</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Bayer : Funding for ESC STEEER-AF trial            Boston Scientific : Funding for ESC STEEER-AF trial            Daiichi Sankyo : Funding for ESC STEEER-AF trial            Boehringer Ingelheim : Funding for ESC STEEER-AF trial            BMS-Pfizer Alliance : Funding for ESC STEEER-AF trial            Amomed : Systematic review            Protherics Medicines Development : Systematic review</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b>            Grants from the UK National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087 and AA/18/2/34218), and the EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074).</p>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Kotecha Dipak	<p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Protherics Medicines Development : Research Methodology</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Bayer : Collaborative systematic review of healthcare coding in HF, Principal Investigator Protherics Medicines Development : Grant for independent systematic review, Principal Investigator Bayer : Unrestricted educational grant to the ESC for the STEEER-AF clinical trial, Chief Investigator Boston Scientific : Unrestricted educational grant to the ESC for the STEEER-AF clinical trial, Chief Investigator Daiichi Sankyo : Unrestricted educational grant to the ESC for the STEEER-AF clinical trial, Chief Investigator Boehringer Ingelheim : Unrestricted educational grant to the ESC for the STEEER-AF clinical trial, Chief Investigator BMS-Pfizer Alliance : Unrestricted educational grant to the ESC for the STEEER-AF clinical trial, Chief Investigator</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> Academic research grants from the National Institute for Health Research (NIHR CDF-2015-08-074; NIHR130280; NIHR132974; NIHR203326); the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032); the EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074; including industry collaboration from Bayer, Novartis, Servier, the HYVE and Vifor); and EU Horizon (HYPERMARKER 101095480; including industry collaboration from Roche, MedicineMan and Microlife).</p>
	<p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b> see section 11</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b> Bayer : Collaborative systematic review of healthcare coding in HF, Principal Investigator Protherics Medicines Development : Grant for independent systematic review, Principal Investigator Bayer : Unrestricted educational grant to the ESC for the STEEER-AF clinical trial, Chief Investigator Boston Scientific : Unrestricted educational grant to the ESC for the STEEER-AF clinical trial, Chief Investigator Daiichi Sankyo : Unrestricted educational grant to the ESC for the STEEER-AF clinical trial, Chief Investigator Boehringer Ingelheim : Unrestricted educational grant to the ESC for the STEEER-AF clinical trial, Chief Investigator BMS-Pfizer Alliance : Unrestricted educational grant to the ESC for the STEEER-AF clinical trial, Chief Investigator</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Kotecha Dipak	<p><b>2023</b> <b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b> Academic research grants from the National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; NIHR132974 D2T-NeuroVascular; NIHR203326 Biomedical Research Centre), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), the EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074; including industry collaboration from Bayer, Novartis, Servier, the HYVE and Vifor); EU Horizon and UKRI (HYPERMARKER 101095480; including industry collaboration from Roche, MedicineMan and Microlife); UK National Health Service -Data for R&amp;D- Subnational Secure Data Environment programme; UK Dept. for Business, Energy &amp; Industrial Strategy Regulators Pioneer Fund; and the Cook &amp; Wolstenholme Charitable Trust. Fellowships panel for the Wellcome Trust (London).</p>
Lettino Maddalena	<p><b>2021</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Boehringer-Ingelheim : anticoagulants Pfizer : anticoagulants Bristol Myers Squibb : anticoagulants Sanofi Aventis : antithrombotic agents and lipid-lowering drugs Edwards Lifesciences : percutaneous cardiac devices</p>
	<p><b>2022</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Bristol Myers Squibb : Atrial Fibrillation (AF), Pharmacology and Pharmacotherapy Novartis : Risk Factors and Prevention Amarin : Risk Factors and Prevention</p>
	<p><b>2023</b> <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Pfizer : Atrial Fibrillation (AF), Pharmacology and Pharmacotherapy Bristol Myers Squibb : Atrial Fibrillation (AF), Pharmacology and Pharmacotherapy Daiichi Sankyo : Risk Factors and Prevention Novartis : Risk Factors and Prevention Amarin : Risk Factors and Prevention</p>
Lochen Maja-Lisa	<p><b>2021</b> Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Lochen Maja-Lisa	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Sanofi Aventis : Acute Coronary Syndromes            BMS/Pfizer : Atrial Fibrillation (AF)            Bayer AG : Atrial Fibrillation (AF)</p>
	<p><b>2023</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            Sanofi Aventis : Atrial Fibrillation (AF)            Bayer AG : Atrial Fibrillation (AF)            BMS/Pfizer : Cardiovascular Disease in Special Populations</p> <p><b>Receipt of royalties for intellectual property.</b>            Gyldendal Akademisk Forlag (Publisher) : Atrial Fibrillation (AF), Cardiovascular Disease in Special Populations</p>
Lumbers Tom	<p><b>2021</b></p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Pfizer : Heart Failure</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b>            I am a discretionary beneficiary of a trust that holds shares in Norgine BV, a pharmaceutical company.</p>
	<p><b>2022</b></p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Pfizer : Genomic research for the identification of drug targets for heart failure , Principal Investigator</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b>            I am a discretionary beneficiary of a trust that holds shares in Norgine BV, a pharmaceutical company.</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Lumbers Tom	<p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b>  British Heart Foundation  Health Data Research UK  Medical Research Council  National Institutes of Health  Pfizer Innovative Target Exploration Network</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>  HealthLumen : Myocardial Disease, Research Methodology  Fitfile : Research Methodology</p> <p><b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b>  Overcome : Chronic Heart Failure, Acute Heart Failure</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b>  Pfizer : Innovative Target Exploration Network Grant: Genomic target identification in heart failure, Principal Investigator</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b>  I am a discretionary beneficiary of a trust that holds shares in Norgine BV, a pharmaceutical company.</p>
Maesen Bart	<p><b>2021</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Medtronic : AF  Atricure : AF</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>  Medtronic : AF</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Maesen Bart	<p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Medtronic : Atrial Fibrillation (AF)            Atricure : Atrial Fibrillation (AF)</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Medtronic : research grant 1 95.000 EUR over 2 years, research grant 2 240.000 EUR over 4 years , PI</p>
	<p><b>2023</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            Atricure : Atrial Fibrillation (AF)</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            Medtronic : Atrial Fibrillation (AF)            Atricure : Atrial Fibrillation (AF)</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b>            Medtronic : PhD student funding, PhD supervisor</p>
Moelgaard Inge	<p><b>2021</b></p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b>            Member of the Danish Heart Association</p>
	<p><b>2022</b></p> <p>Nothing to be declared</p>
	<p><b>2023</b></p> <p>Nothing to be declared</p>
Rienstra Michiel	<p><b>2021</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Roche Diagnostics : Biomarkers            Arca Biopharma Inc : Bucindolol            Medtronic : Diabetes</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Rienstra Michiel	<p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer : Atrial Fibrillation (AF)            InCardaTherapeutics : Atrial Fibrillation (AF)            Microport : Device Therapy</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b>            ESC, EHRA, AHA</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b>            Non-industry research funding: Unrestricted research grant from ZonMW and the Dutch Heart Foundation; DECISION project 848090001. Unrestricted research grants from the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation; RACE V (CVON 2014–9), RED-CVD (CVON2017-11). Unrestricted research grant from Top Sector Life Sciences &amp; Health to the Dutch Heart Foundation (PPP Allowance; CVON-AI (2018B017)). Unrestricted research grant from the European Union’s Horizon 2020 research and innovation programme under grant agreement; EHRA-PATHS (945260)</p> <hr/> <p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one’s ability to join an ESC activity</b>            Dutch Heart Foundation (projects RACE V, RED-CVD, DECISION, EmBRACE)            European Union (project EHRA-PATHS)</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            Bayer (national PI of OCEANIC-AF) : Atrial Fibrillation (AF)            InCarda Therapeutics (national PI of RESTORE-SR) : Atrial Fibrillation (AF)</p>
Rosano Giuseppe	<p><b>2021</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Abbott Laboratories : Dyslipidaemia            Vifor International : Iron Deficiency            Menarini : Ischaemic heart disease / arterial hypertension            Astra Zeneca : speakers fees</p>

## 2024 ESC Guidelines for the management of atrial fibrillation - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Rosano Giuseppe	<p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Astra Zeneca : Chronic Heart Failure  Vifor International : Chronic Heart Failure  Menarini : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)  Abbott Laboratories : Risk Factors and Prevention</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b>  Scientific Board of Heart Failure Policy Network</p>
	<p><b>2023</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>  Astra Zeneca : Chronic Heart Failure  Vifor International : Chronic Heart Failure  Menarini : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)  Abbott Laboratories : Risk Factors and Prevention</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b>  Scientific Board of Heart Failure Policy Network</p>

## 2024 ESC Guidelines for the management of atrial fibrillation - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Sanders Prashanthan	<p><b>2021</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Boston Scientific : Advisory Board            Medtronic : Advisory Board            CathRx : Advisory Board            Abbott Medical : Advisory Board            Pacemate : Advisory Board</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Boston Scientific : CAAN AF            Medtronic : Multiple studies            Microport : Multiple studies            Abbott Medical : Multiple studies            Becton Dickenson : POWDER-CIED</p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b>            Medical Advisory Committee for Hearts4Heart a patient advocacy organization in Australia.</p>
	<p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Abbott Medical : Arrhythmias, General            Medtronic : Arrhythmias, General, Atrial Fibrillation (AF)            CathRx : Arrhythmias, General, Atrial Fibrillation (AF)            Boston Scientific : Chronic Heart Failure, Atrial Fibrillation (AF), Arrhythmias, General            Pacemate : Syncope and Bradycardia, Ventricular Arrhythmias and Sudden Cardiac Death (SCD), Device Therapy</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Becton Dickenson : Clinical trial, Principle Investigator            Boston Scientific : Clinical trials, Principle Investigator            Medtronic : Multiple clinical trials, Site Investigator            Abbott Medical : Multiple clinical trials, Site Investigator</p>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Sanders Prashanthan	<p><b>2022</b> <b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> Supported by the National Health and Medical Research Council of Australia and the National Heart Foundation of Australia</p> <hr/> <p><b>2023</b> <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Abbott Medical : Arrhythmias, General Medtronic : Arrhythmias, General, Atrial Fibrillation (AF) CathRx : Arrhythmias, General, Atrial Fibrillation (AF) Boston Scientific : Arrhythmias, General, Atrial Fibrillation (AF), Chronic Heart Failure Pacemate : Syncope and Bradycardia, Ventricular Arrhythmias and Sudden Cardiac Death (SCD), Device Therapy</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b> Becton Dickenson : Clinical trial, Principle Investigator Boston Scientific : Clinical trials, Principle Investigator Medtronic : Multiple clinical trials, Site Investigator Abbott Medical : Multiple clinical trials, Site Investigator</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b> Supported by the National Health and Medical Research Council of Australia</p>
Schnabel Renate B	<p><b>2021</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> BMS/Pfizer - speaker fees : atrial fibrillation</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> RBS has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme under the grant agreement No 648131, from the European Union’s Horizon 2020 research and innovation programme under the grant agreement No 847770 (AFFECT-EU) and German Center for Cardiovascular Research (DZHK e.V.) (81Z1710103); German Ministry of Research and Education (BMBF 01ZX1408A) and ERACoSysMed3 (031L0239).</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Schnabel Renate B	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Bristol Myers Squibb/Pfizer : Atrial Fibrillation (AF)</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> RBS has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme under the grant agreement No 648131, from the European Union’s Horizon 2020 research and innovation programme under the grant agreement No 847770 (AFFECT-EU) and German Center for Cardiovascular Research (DZHK e.V.) (81Z1710103 and 81Z0710114); German Ministry of Research and Education (BMBF 01ZX1408A) and ERACoSysMed3 (031L0239). Wolfgang Seefried project funding German Heart Foundation.</p>
	<p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one’s ability to join an ESC activity</b> EU, ERACoSysMed3 (031L0239)</p> <p>European Union’s Horizon 2020 research and innovation programme under the grant agreement No 847770 (AFFECT-EU) European Union’s Horizon Europe research and innovation programme under the grant agreement ID: 101095480 German Center for Cardiovascular Research (DZHK e.V.) (81Z1710103 and 81Z0710114) German Ministry of Research and Education (BMBF 01ZX1408A)</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Pfizer : Atrial Fibrillation (AF) Bristol Myers Squibb : Atrial Fibrillation (AF) Bayer Healthcare : Chronic Heart Failure</p>
Suwalski Piotr	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Medtronic : speaker bureau, minimally invasive surgical valve coronary and arrhythmia treatment Atricure : speaker bureau, minimally invasive surgical valve coronary and arrhythmia treatment</p>
	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Medtronic : 4 items checked Atricure : Atrial Fibrillation (AF)</p>

## 2024 ESC Guidelines for the management of atrial fibrillation - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Suwalski Piotr	<p><b>2023</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            Medtronic : 4 items checked            Atricure : Atrial Fibrillation (AF)</p>
Svennberg Emma	<p><b>2021</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Pfizer : Atrial Fibrillation            Johnson &amp; Johnson : Atrial Fibrillation            Merck Sharp &amp; Dohme : Atrial Fibrillation            Bayer : NOAC            Boehringer-Ingelheim : NOACs            Bristol Myers Squibb : NOACs</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b>            Member of HRS digital committee (non-paid) Member of executive board for AF Screen International (non-paid)</p>
	<p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Pfizer : Arrhythmias, General            Bayer : Atrial Fibrillation (AF)            Boehringer-Ingelheim : Atrial Fibrillation (AF)            Johnson &amp; Johnson : Atrial Fibrillation (AF)            Bristol Myers Squibb : Atrial Fibrillation (AF)            Merck Sharp &amp; Dohme : Atrial Fibrillation (AF)</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b>            Member and part of steering committee for AF Screen International Collaboration</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Svennberg Emma	<p><b>2023</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            Pfizer : Arrhythmias, General            Abbott : Atrial Fibrillation (AF)            Astra Zeneca : Atrial Fibrillation (AF)            Bayer : Atrial Fibrillation (AF)            Johnson &amp; Johnson : Atrial Fibrillation (AF)            Bristol Myers Squibb : Atrial Fibrillation (AF)            Merck Sharp &amp; Dohme : Atrial Fibrillation (AF)</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b>            Member and part of steering committee for AF Screen International Collaboration</p>
Tamargo Juan	<p><b>2021</b> Nothing to be declared</p> <p><b>2022</b> Nothing to be declared</p> <p><b>2023</b> Nothing to be declared</p>
Tica Otilia	<p><b>2021</b> Nothing to be declared</p> <p><b>2022</b></p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>            Sun Wave Pharma : Other</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b>            ESC Young National Ambassador for Acute Cardiovascular Care Association ESC ACVC Task Force on Digital Health WG on Aorta &amp; Peripheral Vascular Diseases Member WG on e-Cardiology Member WG on Adult Congenital Heart Disease Member Council on Stroke Regular Member EAPCI Regular Member EAPC Regular Member Romanian Society of Cardiology Member Young 35, Core leader for the Young Cardiologist of the Romanian Society of Cardiology</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Tica Otilia	<p><b>2023</b></p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b>            ESC Young National Ambassador for Acute Cardiovascular Care Association ESC- HFA Scientific Committee on Acute Heart Failure            ESC- HFA Scientific Committee on Atrial Disorders ESC ACVC Task Force on Digital Health WG on Aorta &amp; Peripheral Vascular Diseases Member WG on e-Cardiology Member WG on Adult Congenital Heart Disease Member Council on Stroke Regular Member EAPCI Regular Member EAPC Regular Member Romanian Society of Cardiology Member Young 35, Core leader for the Young Cardiologist of the Romanian Society of Cardiology</p>
Traykov Vassil	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Abbott : Consultancy fee            Teva Pharmaceutical Industries : ECG            Bayer : NOAC            Boehringer-Ingelheim : NOAC            Pfizer : NOAC            Berlin Menarini : NOAC            Merck Sharp &amp; Dohme : Pharmacological treatment of arrhythmias - beta blockers            Novartis : Prevention of cardiac disease - unrelated to any specific product            Astra Zeneca : SGLT2i            Medtronic : Sudden cardiac death</p> <hr/> <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Boehringer-Ingelheim : Atrial Fibrillation (AF), Pharmacology and Pharmacotherapy            Abbott : Supraventricular Tachycardia (Non-Atrial Fibrillation)            Servier : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>            Johnson &amp; Johnson : Atrial Fibrillation (AF)            Astra Zeneca : Chronic Heart Failure</p>

## 2024 ESC Guidelines for the management of atrial fibrillation - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Traykov Vassil	<p><b>2023</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            Johnson &amp; Johnson : Atrial Fibrillation (AF)            Novartis : Chronic Heart Failure            Biotronik : Device Therapy            Abbott : Supraventricular Tachycardia (Non-Atrial Fibrillation)</p> <p><b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b>            Pfizer : Chronic Heart Failure</p>
Tzeis Stylianos	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Abbott : Speaker fees, advisory board fees, honoraria            Bayer : Speaker fees, advisory board fees, honoraria            Pfizer : Speaker fees, advisory board fees, honoraria            Biosense Webster : Speaker fees, advisory board fees, honoraria</p> <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer : Atrial Fibrillation (AF)            Pfizer : Atrial Fibrillation (AF)</p> <p><b>2023</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            Bayer : Atrial Fibrillation (AF)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Van Gelder Isabelle C	<p><b>2021</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer AG : Atrial fibrillation stroke prevention            Boston Scientific : Atrial fibrillation            Medtronic : Atrial fibrillation            Pfizer : Atrial fibrillation            Roche Diagnostics : Atrial fibrillation</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Medtronic : Atrial fibrillation</p>
	<p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer AG : Stroke</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Medtronic : RACE V AF progression study, principle investigator</p>
	<p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b>            Dutch Heart Foundation (NHS)</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            Bayer : Atrial Fibrillation (AF)</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b>            Dutch Heart Foundation : atrial fibrillation - large consortium EMbRACE, PI</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry	
Abdrakhmanov Ayan	<b>2022</b>	Nothing to be declared
	<b>2023</b>	<b>Employment (including part time) in healthcare industry during the year for which you are declaring.</b> Astana Medical University : Head of Cardiology Department
Ahsan Syed	<b>2022</b>	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Atricure : Atrial Fibrillation (AF)
	<b>2023</b>	<b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b> Biosense webster : FUNDING FOR POSTGRADUATE RESEARCH FELLOWSHIP, Chief investigator
Ameri Pietro	<b>2022</b>	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Astra Zeneca : Chronic Heart Failure, Pharmacology and Pharmacotherapy Boehringer-Ingelheim : Chronic Heart Failure, Pharmacology and Pharmacotherapy Novartis : Chronic Heart Failure, Pharmacology and Pharmacotherapy Janssen-Cilag : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure, Pharmacology and Pharmacotherapy Merck Sharp & Dohme : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure, Pharmacology and Pharmacotherapy <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Astra Zeneca : Chronic Heart Failure, Acute Heart Failure, Pharmacology and Pharmacotherapy <b>Travel and meeting support from healthcare industry, independent of the above activities.</b> Daiichi Sankyo : Atrial Fibrillation (AF)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Ameri Pietro	<p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b> Italian Ministry of Health</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Daiichi Sankyo : Atrial Fibrillation (AF) Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Bayer AG : Chronic Heart Failure Janssen-Cilag : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure Merck Sharp &amp; Dohme : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure</p>
Arbelo Elena	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Biosense Webster : Atrial Fibrillation (AF)</p> <hr/> <p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b> Marató TV3</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Bayer : Atrial Fibrillation (AF) Biosense Webster : Atrial Fibrillation (AF)</p>
Avraamides Panayiotis	<p><b>2022</b></p> <p>Nothing to be declared</p> <hr/> <p><b>2023</b></p> <p>Nothing to be declared</p>
Barysiene Jurate	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Servier : Arrhythmias, General Bayer : Atrial Fibrillation (AF) Pfizer : Atrial Fibrillation (AF)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Barysiene Jurate	<b>2022</b> <b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> Lithuanian Society of Cardiology Lithuanian Heart Association
	<b>2023</b> <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Bayer : Atrial Fibrillation (AF) Pfizer : Atrial Fibrillation (AF) Servier : Atrial Fibrillation (AF)
Bauer Axel	<b>2022</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Medtronic : e-Cardiology/Digital Health Pfizer : e-Cardiology/Digital Health Boston Scientific : Other Daiichi Sankyo : Other Biotronik : Other Siemens Healthcare : Other Edwards Lifesciences : Valvular Heart Disease <b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Pfizer : Support for clinical trial on digital AF screening , principal investigator
	<b>2023</b> <b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b> Ludwig-Boltzmann-Gesellschaft <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Daiichi Sankyo : Atrial Fibrillation (AF) Biotronik : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Bristol Myers Squibb : Other
Bheleel Osama	<b>2022</b> Nothing to be declared
	<b>2023</b> Nothing to be declared

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Bjorkenheim Anna	<p><b>2022</b> Nothing to be declared</p> <hr/> <p><b>2023</b> <b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b>            Swedish Heart Lung Foundation            Swedish Research Council</p>
Borger Michael A	<p><b>2022</b> <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Artivion (formerly CryoLife) : Diseases of the Aorta            Abbott : Valvular Heart Disease            Edwards Lifesciences : Valvular Heart Disease            Medtronic : Valvular Heart Disease</p> <hr/> <p><b>2023</b> <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            Artivion (formerly CryoLife) : Diseases of the Aorta            Abbott : Valvular Heart Disease            Edwards Lifesciences : Valvular Heart Disease            Medtronic : Valvular Heart Disease</p>
Brandes Axel	<p><b>2022</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bristol Myers Squibb : Atrial Fibrillation (AF)</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Theravance Biopharma Ireland Ltd. : Participation in a multi-centre study in patients with neurogen ortostatik hypertension, Principal investigator</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b>            Danish Heart Foundation</p> <hr/> <p><b>2023</b> <b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b>            Danish Heart Foundation</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Buccheri Sergio	<b>2022</b> Nothing to be declared
	<b>2023</b> Nothing to be declared
Bytyci Ibadete	<b>2022</b> Nothing to be declared
	<b>2023</b> Nothing to be declared
Calvo Cuervo David	<b>2022</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Abbott : Arrhythmias, General Bristol Myers Squibb : Atrial Fibrillation (AF) Biosense Webster : Atrial Fibrillation (AF)  <b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> President Spanish Heart Rhythm Association
	<b>2023</b> <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Abbott : Arrhythmias, General Bristol Myers Squibb : Atrial Fibrillation (AF) Biosense Webster : Atrial Fibrillation (AF)  <b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> Past-president Spanish Heart Rhythm Association
Casadei Barbara	<b>2022</b> <b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> I-Rhythm : in-kind support (free ECG monitors) for a research project, Co-PI  <b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> British Heart Foundation UK Academy of Medical Sciences (Fellow) Women As One (Board member) Association of Physicians GB & Northern Ireland - Board of Trustees Board member of the WHF (ended in sept 2022) UKRI Medical Research Council - Population and Systems Medicine Board member International Science Advisory Board of the Netherlands Heart Institute (NHI), Chair Translational Research Group, German Centre for Cardiovascular Research (DZHK TRG) Scientific Advisory Board of the Max Delbrück Centre for Molecular Medicine in the Helmholtz Association, Germany Scientific Advisory Committee of Fondation Leducq IHU LIRYC Research Institute, Bordeaux, France, Board member.

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Casadei Barbara	<p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b> British Heart Foundation NIHR</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> British Heart Foundation UK Academy of Medical Sciences (Fellow) Women As One (Board member) Association of Physicians GB &amp; Northern Ireland - Board of Trustees International Science Advisory Board of the Netherlands Heart Institute (NHI), Chair Scientific Advisory Board of the Max Delbrück Centre for Molecular Medicine in the Helmholtz Association, Germany Scientific Advisory Committee of Fondation Leducq (President) IHU LIRYC Research Institute, Bordeaux, France, Board member Scientific Advisory Board, CADENCE, Consortium for Clinical Research and Innovation, Singapore</p>
Chioncel Ovidiu	<p><b>2022</b></p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b> Servier : Chronic Heart Failure</p>
	<p><b>2023</b></p> <p><b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b> Servier ESC 2023 Congress attendance support : Chronic Heart Failure</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b> Associate Editor: BMC Cardiovascular Disorders Exploration in Medicine Cardiac Failure Review Journal of Acute Disease</p>
Colivicchi Furio	<p><b>2022</b></p> <p>Nothing to be declared</p>
	<p><b>2023</b></p> <p>Nothing to be declared</p>
Cools Frank	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Daiichi Sankyo : Pharmacology and Pharmacotherapy Novo-Nordisk : Risk Factors and Prevention</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Eli Lilly : participation in clinical trial, PI Biotronik : research grant, investigatir Abbott : research grant, investigator</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Cools Frank	<p><b>2023</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Novo-Nordisk : Risk Factors and Prevention</p> <p><b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b> Novo-Nordisk : European Society of Cardiology</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b> Abbott : research grant, investigator Biotronik : research grant, investigator Birotronik : research grant, investigator</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b> editor of Acta Cardiologica, non paid job</p>
Cozma Dragos Constantin	<p><b>2022</b> Nothing to be declared</p> <p><b>2023</b> Nothing to be declared</p>
Dagres Nikolaos	<p><b>2022</b> Nothing to be declared</p> <p><b>2023</b> Nothing to be declared</p>
Demircan Sabri	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Bayer : Atrial Fibrillation (AF) Menarini : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p> <p><b>2023</b> Nothing to be declared</p>
Dobrev Dobromir	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> AbbiVie : Atrial Fibrillation (AF) Daiichi Sankyo : Pharmacology and Pharmacotherapy, Other</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Dobrev Dobromir	<p><b>2023</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            TMA Foundation : Atrial Fibrillation (AF)            Daiichi Sankyo : Pharmacology and Pharmacotherapy, Other</p>
Eckardt Lars	<p><b>2022</b></p> <p>Nothing to be declared</p>
	<p><b>2023</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            Boston Scientific : Arrhythmias, General            Daiichi Sankyo : Arrhythmias, General            Novartis : Arrhythmias, General            Biotronik : Arrhythmias, General            Abbott Laboratories : Arrhythmias, General            Thieme Verlag : Arrhythmias, General            German Cardiac Society : Arrhythmias, General            Kelcon : Arrhythmias, General</p>
Eldamaty Ahmed	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Abbott : Clinical Skills            Boston Scientific : Training and Education</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>            Abbott : Training and Education</p>
	<p><b>2023</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            Abbott : Clinical Skills            Boston Scientific : Training and Education</p> <p><b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b>            Abbott : Training and Education</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Etsadashvili Kakhaber	<p><b>2022</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Bayer AG : Atrial Fibrillation (AF), Chronic Heart Failure, Stroke  Servier : Peripheral Vascular and Cerebrovascular Disease, Stroke, Pharmacology and Pharmacotherapy, Other</p>
	<p><b>2023</b>     <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>  Servier : Peripheral Vascular and Cerebrovascular Disease, Stroke, Pharmacology and Pharmacotherapy, Other</p>
Fauchier Laurent	<p><b>2022</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Astra Zeneca : Pharmacology and Pharmacotherapy  Bayer : Pharmacology and Pharmacotherapy  Boehringer-Ingelheim : Pharmacology and Pharmacotherapy  Novartis : Pharmacology and Pharmacotherapy  Servier : Pharmacology and Pharmacotherapy  BMS/Pfizer : Pharmacology and Pharmacotherapy  Novo-Nordisk : Pharmacology and Pharmacotherapy</p>
	<p><b>2023</b>     <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>  Medtronic : Device Therapy  Astra Zeneca : Pharmacology and Pharmacotherapy  Bayer : Pharmacology and Pharmacotherapy  Boehringer-Ingelheim : Pharmacology and Pharmacotherapy  Servier : Pharmacology and Pharmacotherapy  BMS/Pfizer : Pharmacology and Pharmacotherapy  Novo-Nordisk : Pharmacology and Pharmacotherapy  Leo Pharma : Pharmacology and Pharmacotherapy</p>
Fink Trine	<p><b>2022</b>     Nothing to be declared</p>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Fink Trine	<p><b>2023</b> Nothing to be declared</p>
Garcia Rodrigue	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Boston Scientific : Chronic Heart Failure            Sorin Group : Research Methodology            Medtronic : Training and Education</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>            Sorin Group : Arrhythmias, General</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Boston Scientific : Grant for research activity related to heart failure, chief investigator</p>
	<p><b>2023</b></p> <p><b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b>            Sorin Group : Arrhythmias, General</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b>            Boston Scientific : Grant for research activity related to heart failure, chief investigator</p>
Geller Laszlo Alajos	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Abbott : Atrial Fibrillation (AF), Device Therapy            Medtronic : Device Therapy            Biotronik : Device Therapy</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>            Medtronic : Device Therapy</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Geller Laszlo Alajos	<p><b>2023</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            Abbott : Atrial Fibrillation (AF), Device Therapy            Medtronic : Device Therapy            Biotronik : Device Therapy</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            Medtronic : Training and Education</p>
Gigante Bruna	<p><b>2022</b> Nothing to be declared</p> <hr/> <p><b>2023</b> Nothing to be declared</p>
Glikson Michael	<p><b>2022</b> Nothing to be declared</p> <hr/> <p><b>2023</b> <b>Research funding from healthcare industry received personally by you or an entity controlled by you.</b>            Medtronic</p>
GROSU Aurel	<p><b>2022</b> Nothing to be declared</p> <hr/> <p><b>2023</b> Nothing to be declared</p>
Gudmundsson Kristjan	<p><b>2022</b> Nothing to be declared</p> <hr/> <p><b>2023</b> Nothing to be declared</p>
Hijazi Ziad	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Boehringer-Ingelheim : Atrial Fibrillation (AF)            Pfizer : Atrial Fibrillation (AF)            Bristol Myers Squibb : Atrial Fibrillation (AF)            Roche Diagnostics : Atrial Fibrillation (AF)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Hijazi Ziad	<p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b>  Hjärt-Lungfonden (The Swedish Heart-Lung Foundation)  The Swedish Society for Medical Research  Uppsala University Hospital</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>  Boehringer-Ingelheim : Atrial Fibrillation (AF)  Pfizer : Atrial Fibrillation (AF)  Bristol Myers Squibb : Atrial Fibrillation (AF)  Roche Diagnostics : Atrial Fibrillation (AF)</p>
Hindricks Gerhard	<p><b>2022</b> Nothing to be declared</p> <hr/> <p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b>  European Commission</p>
Hlivak Peter	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Pfizer : Atrial Fibrillation (AF)  Boehringer-Ingelheim : Chronic Heart Failure  Bayer : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)  Novo-Nordisk : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Novo-Nordisk : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Hlivak Peter	<p><b>2023</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Pfizer : Atrial Fibrillation (AF) Boehringer-Ingelheim : Chronic Heart Failure Bayer : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Novo-Nordisk : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Novo-Nordisk : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p>
Husser Daniela	<p><b>2022</b> Nothing to be declared</p> <p><b>2023</b> Nothing to be declared</p>
Ibanez Borja	<p><b>2022</b></p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomia, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).</p> <p><b>2023</b></p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b> My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomia, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).</p>
James Stefan	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Medtronic : Valvular Heart Disease</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Amgen : Executive committee member, Executive committee member Janssen-Cilag : Executive committee member, Executive committee member Astra Zeneca : Study PI , Prinicpal investigator</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
James Stefan	<p><b>2022</b>    <b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> Swedish medical Association, Swedish cardiac society</p> <hr style="border-top: 1px dashed black;"/> <p><b>2023</b>    <b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b> Wallenberg foundation, Swedish heart and lung foundation</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Medtronic : Valvular Heart Disease</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b> Elixir : clinical trial, study chair MSD : Clinical trial, trial executive committee Amgen : Executive committee member, Executive committee member Janssen-Cilag : Executive committee member, Executive committee member Astra Zeneca : Study PI , Principial investigator</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> Swedish medical Association, Swedish cardiac society</p>
Kaab Stefan	<p><b>2022</b>    <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Boehringer-Ingelheim : Chronic Heart Failure, Acute Heart Failure, Pharmacology and Pharmacotherapy, Public Health and Health Economics Bayer Healthcare : Chronic Heart Failure, Public Health and Health Economics, Training and Education Bristol Myers Squibb : Congenital Heart Disease and Paediatric Cardiology, Pharmacology and Pharmacotherapy, Training and Education</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> DGIM (Deutsche Gesellschaft für Innere Medizin / German Society of Internal Medicine) regular member BDI (Berufsverband Deutscher Internisten / German Internal Medicine Association) regular member, program committee</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Kaab Stefan	<p><b>2023</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            Bristol Myers Squibb : 3 items checked            Boehringer-Ingelheim : 4 items checked</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b>            DGK (German Cardiac Society) DGIM (Deutsche Gesellschaft für Innere Medizin / German Society of Internal Medicine) regular member            BDI (Berufsverband Deutscher Internisten / German Internal Medicine Association) regular member, program committee</p>
Kallergis Eleftherios	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Abbott : Arrhythmias, General, Atrial Fibrillation (AF), Supraventricular Tachycardia (Non-Atrial Fibrillation), Ventricular Arrhythmias and Sudden Cardiac Death (SCD)            Medtronic : Atrial Fibrillation (AF)            Pfizer : Atrial Fibrillation (AF)            Boston Scientific : Atrial Fibrillation (AF), Ventricular Arrhythmias and Sudden Cardiac Death (SCD), Device Therapy            Novartis : Ventricular Arrhythmias and Sudden Cardiac Death (SCD), Chronic Heart Failure, Acute Heart Failure</p> <p><b>2023</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            Abbott : 4 items checked            Medtronic : Atrial Fibrillation (AF)            Pfizer : Atrial Fibrillation (AF)            Boston Scientific : Atrial Fibrillation (AF), Ventricular Arrhythmias and Sudden Cardiac Death (SCD), Device Therapy            Novartis : Ventricular Arrhythmias and Sudden Cardiac Death (SCD), Chronic Heart Failure, Acute Heart Failure</p>
Kampus Priit	<p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Abbott Estonia : Device Therapy</p> <p><b>2023</b></p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Kazmierczak Jaroslaw	<p><b>2022</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Astra Zeneca : Chronic Heart Failure  Medtronic : Device Therapy  Amgen : Risk Factors and Prevention  Novartis : Risk Factors and Prevention  Sanofi Aventis : Risk Factors and Prevention  Zoll Medical : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p>
	<p><b>2023</b>     <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>  Boehringer Ingelheim : Chronic Heart Failure  Medtronic : Device Therapy  Polfarma Poland : Pharmacology and Pharmacotherapy  NDG Medical : Pharmacology and Pharmacotherapy  Novartis : Risk Factors and Prevention  Zoll Medical : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p>
Kerimkulova Alina	<p><b>2022</b>     Nothing to be declared</p>
	<p><b>2023</b>     Nothing to be declared</p>
Kichou Brahim	<p><b>2022</b>     Nothing to be declared</p>
	<p><b>2023</b>     Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Kirchhof Paulus	<p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Daiichi Sankyo : Atrial Fibrillation (AF)  Medtronic : Atrial Fibrillation (AF)  Roche Diagnostics : Atrial Fibrillation (AF)  Philips : e-Cardiology/Digital Health  Astra Zeneca : Training and Education  Boehringer-Ingelheim : Training and Education  Johnson&amp;Johnson : Training and Education</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>  European Union horizon2020 : different EU projects, project partner, project lead  British Heart Foundation : different research grants, project leader, senior fellow,  NIHR (UK National Institute of Health Research) : funding for the RATE-AF trial, supervisor for fellowship  Leducq Foundation : genomics and AF network, PI  UK Medical Research Council : project co lead, coapplicant  German Ministry of Education and Research (BMBF) : support for clinical trials, different roles in different t  Abbott : support for EAST - AFNET 4, chief investigator  Sanofi Aventis : support for EAST - AFNET 4, chief investigator  Daiichi Sankyo : support for NOAH - AFNET 6, CHief Investigator</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b>  speaker of the board of AFNET</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b>  the UKE holds two patents related to atrial fibrillation. I am listed as an inventor. No licensing or royalties.</p>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Kirchhof Paulus	<p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b>  Deutsche Forschungsgemeinschaft  European Union (different h2020 projects)  German Center for Cardiovascular Research (DZHK) funded by the German Ministry of Education and Research</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>  Daiichi Sankyo : Atrial Fibrillation (AF)  Novartis : Atrial Fibrillation (AF)  Bayer AG : Atrial Fibrillation (AF)  Acesion Pharma : Atrial Fibrillation (AF)  Astra Zeneca : Training and Education  Boehringer-Ingelheim : Training and Education  Pfizer : Training and Education</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b>  Sanofi Aventis : support for EAST - AFNET 4, chief investigator  Daiichi Sankyo : support for NOAH - AFNET 6, Chief Investigator</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b>  speaker of the board of AFNET</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b>  the UKE holds two patents related to atrial fibrillation. I am listed as an inventor. No licensing or royalties.</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Kober Lars	<p><b>2022</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Astra Zeneca : Chronic Heart Failure  Bayer : Chronic Heart Failure  Boehringer-Ingelheim : Chronic Heart Failure  Novartis : Chronic Heart Failure</p>
	<p><b>2023</b>     <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>  Astra Zeneca : Chronic Heart Failure  Boehringer-Ingelheim : Chronic Heart Failure  Novartis : Chronic Heart Failure  Novo-Nordisk : Chronic Heart Failure</p>
Koskinas Konstantinos	<p><b>2022</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Amgen : Risk Factors and Prevention  Daiichi Sankyo : Risk Factors and Prevention  Sanofi Aventis : Risk Factors and Prevention  <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p>
	<p><b>2023</b>     <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>  Amgen : Risk Factors and Prevention  Daiichi Sankyo : Risk Factors and Prevention  Sanofi Aventis : Risk Factors and Prevention</p>
Kovacevic Dragan	<p><b>2022</b>     Nothing to be declared</p>
	<p><b>2023</b>     Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Kuchkarov Husniddin	<b>2022</b> <b>Employment (including part time) in healthcare industry during the year for which you are declaring.</b> Republican Specialized Scientific - Practical medical center of cardiology : Researcher
	<b>2023</b> <b>Employment (including part time) in healthcare industry during the year for which you are declaring.</b> Republican Specialized Scientific - Practical medical center of cardiology : Researcher
Kuhne Michael	<b>2022</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Daiichi Sankyo : Atrial Fibrillation (AF)  <b>Receipt of royalties for intellectual property.</b> Springer : Arrhythmias, General
	<b>2023</b> <b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b> Swiss National Science Foundation  <b>Receipt of royalties for intellectual property.</b> Springer : Arrhythmias, General
Kumler Thomas	<b>2022</b> <b>Travel and meeting support from healthcare industry, independent of the above activities.</b> Medtronic : Device Therapy
	<b>2023</b> <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Medtronic : Atrial Fibrillation (AF)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Kupics Kaspars	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer : Atrial Fibrillation (AF)            Servier : Atrial Fibrillation (AF)            Biosense Webster : Atrial Fibrillation (AF)            Viartis : Atrial Fibrillation (AF)            Boston Scientific : Device Therapy</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>            Bayer : Arrhythmias, General            Servier : Arrhythmias, General            Biosense Webster : Arrhythmias, General            Medtronic : Device Therapy</p> <hr style="border-top: 1px dashed black;"/> <p><b>2023</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            Boston Scientific : Arrhythmias, General            Johnson &amp; Johnson : Atrial Fibrillation (AF)            Biotronik : Device Therapy</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            Bayer : Arrhythmias, General            Boston Scientific : Arrhythmias, General            Servier : Arrhythmias, General            Biotronik : Arrhythmias, General</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b>            Latvian Cardiology Association, board member</p>
Leitz Patrick	<p><b>2022</b></p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry	
Leitz Patrick	<b>2023</b>	Nothing to be declared
Lip Gregory Yh	<b>2022</b>	<p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Pfizer : Atrial Fibrillation (AF)            Daiichi-Sankyo : Atrial Fibrillation (AF)            Boehringer Ingelheim : Atrial Fibrillation (AF)            BMS : Atrial Fibrillation (AF)</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Boehringer-Ingelheim : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries., Principal Investigator</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b>            Shares in private limited company (a legal separate entity in UK), but no salary/dividends/income/personal remuneration received.</p>
	<b>2023</b>	<p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b>            Boehringer-Ingelheim : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellow., Principal Investigator            Anthos : AF registries [unrestricted educational grant]. Academic, non promotional research work on registries by fellow., Principal Investigator</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b>            Shares in private limited company (a legal separate entity in UK), but no salary/income/personal remuneration received.</p>
Lyne Jonathan	<b>2022</b>	<p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Medtronic : Device Therapy</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Medtronic : Device Therapy</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Lyne Jonathan	<b>2023</b> <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Medtronic : Device Therapy
Mandrola John	<b>2022</b> Nothing to be declared <hr/> <b>2023</b> Nothing to be declared
Manola Sime	<b>2022</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Krka Pharma : Arrhythmias, General <b>Travel and meeting support from healthcare industry, independent of the above activities.</b> Biosense Webster : Atrial Fibrillation (AF) <hr/> <b>2023</b> <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Boehringer-Ingelheim : Chronic Heart Failure, Acute Heart Failure
Marai Ibrahim	<b>2022</b> Nothing to be declared <hr/> <b>2023</b> Nothing to be declared
Marx Nikolaus	<b>2022</b> <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Astra Zeneca : Other Bayer : Other Novo-Nordisk : Other MSD : Other Boehringer Ingelheim / Lilly : Other

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Marx Nikolaus	<p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b> Deutsche Forschungsgemeinschaft (German Research Foundation; TRR 219; Project-ID 322900939 [M03, M05])</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Amgen : Other Astra Zeneca : Other Bayer : Other Daiichi Sankyo : Other Sanofi Aventis : Other Novo-Nordisk : Other Genfit SA : Other MSD : Other Boehringer Ingelheim / Lilly : Other</p>
Mcevoy John William	<p><b>2022</b> Nothing to be declared</p> <p><b>2023</b> Nothing to be declared</p>
Mihaylova Borislava	<p><b>2022</b></p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Merck Sharp &amp; Dohme : economic analyses alongside a clinical trial, senior health economist Barts Charity : Research project, principal investigator National Institute for Health Research (UK), Health Technology Assessment Programme : Research project, principal investigator Bowel Research UK : research project, principal investigator</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Mihaylova Borislava	<p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b></p> <p>Barts Charity, UK Bowel Research UK Cancer Research UK National Institute for Health and Care Research, UK</p>
Mindham Richard	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> PASSpaces. <a href="http://passpaces.co.uk/">http://passpaces.co.uk/</a>. PASSpaces tutors young British doctors to help them pass their medical examinations. I "act" as a patient, permitting the trainee to take a patient history. : Training and Education</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b> European Society of Cardiology. Payment of hotel, travel and meals to attend or speak at ESC conferences. : European Society of Cardiology</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> I support the British charity CardiomyopathyUK, <a href="https://www.cardiomyopathy.org.uk/">https://www.cardiomyopathy.org.uk/</a>. I make small financial contributions to support their activities. I support the British charity Pumping Marvellous, <a href="https://pumpingmarvellous.org/">https://pumpingmarvellous.org/</a>. I make no financial contributions to the charity's activities. I am a member of the Coalition for Reducing Bureaucracy in Clinical Trials, <a href="https://bureaucracyincts.eu/">https://bureaucracyincts.eu/</a>. The Coalition is a collection of researchers, clinicians and patients which advocates for the reduction of bureaucracy in clinical trials, chiefly in the EU. I have no financial interest in the Coalition.</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> I have savings and pensions held in shares. The shares are managed by a financial adviser; I do not not control the purchase &amp; sale of shares and I do not know whether any shares are in medical companies.</p>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Mindham Richard	<p><b>2023</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            NiCE (National Institute for Health &amp; Care Excellence) - UK Government body. Guideline development.. Commences January 2024. : Chronic Heart Failure</p> <p>PASSpaces. <a href="http://passpaces.co.uk/">http://passpaces.co.uk/</a>. PASSpaces tutors young British doctors to help them pass their medical examinations. I "act" as a patient, permitting the trainee to take a patient history. : Training and Education</p> <p><b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b>            European Society of Cardiology. Payment of hotel, travel and meals to attend or speak at ESC conferences. : European Society of Cardiology</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b>            I support the British charity CardiomyopathyUK, <a href="https://www.cardiomyopathy.org.uk/">https://www.cardiomyopathy.org.uk/</a>. I make small financial contributions to support their activities. I support the British charity Pumping Marvellous, <a href="https://pumpingmarvellous.org/">https://pumpingmarvellous.org/</a>. I make no financial contributions to the charity's activities. I am a member of the Coalition for Reducing Bureaucracy in Clinical Trials, <a href="https://bureaucracyincts.eu/">https://bureaucracyincts.eu/</a>. The Coalition is a collection of researchers, clinicians and patients which advocates for the reduction of bureaucracy in clinical trials, chiefly in the EU. I have no financial interest in the Coalition.</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b>            I have savings and pensions held in shares. The shares are managed by a financial adviser; I do not not control the purchase &amp; sale of shares and I do not know whether any shares are in medical companies.</p>
Moustaghfir Abdelhamid	<p><b>2022</b> Nothing to be declared</p> <p><b>2023</b> Nothing to be declared</p>
Muraru Denisa	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Philips : Cross-Modality and Multi-Modality Imaging Topics            GE Healthcare : Echocardiography</p> <p><b>2023</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            Philips : Cross-Modality and Multi-Modality Imaging Topics            GE Healthcare : Echocardiography</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Neubeck Lis	<p><b>2022</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Pfizer : Atrial Fibrillation (AF),</p>
	<p><b>2023</b>     <b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b> Burdett Trust for Nursing Chief Scientists Office</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Sanofi Aventis : Risk Factors and Prevention</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b> Daiichi Sankyo : Atrial fibrillation screening, Principal Investigator</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b> Consultant Editor British Journal of Cardiac Nursing</p>
Ng Ghulam Andre	<p><b>2022</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Biosense Webster : Arrhythmias, General, Atrial Fibrillation (AF)</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Abbott : Clinical Research Fellow salary support paid to the University of Leicester - research in atrial fibrillation: novel mapping, innovation and ablation techniques, Research Supervisor</p> <p>Biosense Webster : Clinical Training Fellow salary support paid to the University of Leicester - focus in atrial fibrillation: novel mapping, innovation and ablation techniques, Clinical Supervisor</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Ng Ghulam Andre	<p><b>2023</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Biosense Webster : Arrhythmias, General, Atrial Fibrillation (AF)</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b> Abbott : Clinical Research Fellow salary support paid to the University of Leicester - research in atrial fibrillation: novel mapping, innovation and ablation techniques, Research Supervisor Biosense Webster : Clinical Training Fellow salary support paid to the University of Leicester - focus in atrial fibrillation: novel mapping, innovation and ablation techniques, Clinical Supervisor</p>
Nielsen Jens Cosedis	<p><b>2022</b></p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> Have received research funding to my institution for independent research from the Danish Heart Foundation and the Novo Nordisk Foundation.</p> <p><b>2023</b></p> <p>Nothing to be declared</p>
Oldgren Jonas	<p><b>2022</b></p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Roche Diagnostics : Academic Registry-based RCT in atrial fibrillation. Financial support from three national academic funding bodies + Roche Diagnostics. No support from Roche for my own activity, Principal investigator Astrazeneca : International RCT evaluating dapagliflozin post Myocardial infarction (DAPA-MI) performed in collaboration between AstraZeneca and Uppsala Clinical Research Center , Chair Executive committee Bayer : Multinational RCTs of asundexian vs apixaban for stroke prevention in atrial fibrillation. PACIFIC-AF 2019-2022 and OCEANIC-AF from 2022, Executive committee member Novartis : Planning of a randomized clinical trial post myocardial infarction (never launched), Academic expert</p> <p><b>2023</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Amgen : Acute Coronary Syndromes Astra Zeneca : Acute Coronary Syndromes Bayer AG : Atrial Fibrillation (AF) Roche Diagnostics : Atrial Fibrillation (AF)</p>
Ouali Sana	<p><b>2022</b></p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry	
Ouali Sana	<b>2023</b>	Nothing to be declared
Paciaroni Maurizio	<b>2022</b>	<p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Daiichi Sankyo : Atrial Fibrillation (AF), Stroke            Pfizer : Atrial Fibrillation (AF), Stroke            Bristol Myers Squibb : Atrial Fibrillation (AF), Stroke            Sanofi Aventis : Peripheral Vascular and Cerebrovascular Disease, Stroke, Risk Factors and Prevention</p>
	<b>2023</b>	<p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            Sanofi Aventis : 3 items checked            Daiichi Sankyo : Atrial Fibrillation (AF), Stroke            Pfizer : Atrial Fibrillation (AF), Stroke</p>
Pasquet Agnes A	<b>2022</b>	<p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Philips : Echocardiography, Interventional Cardiology            Daiichi Sankyo : Hypertension            Servier : Other</p>
	<b>2023</b>	<p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            Servier : Hypertension</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            Servier : Hypertension</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b>            Philips : echography, contribution and support</p>
Pavlovic Nikola	<b>2022</b>	Nothing to be declared

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry	
Pavlovic Nikola	<b>2023</b>	Nothing to be declared
Prescott Eva	<b>2023</b>	Nothing to be declared
Raatikainen Pekka	<b>2022</b>	<p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Stereotaxis : Arrhythmias, General            Biosense Webster : Arrhythmias, General            Pfizer / BMS Alliance : Pharmacology and Pharmacotherapy</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Biosense Webster : Investigator initiated international multicenter study (MANTRA-VT), Principal Investigator</p>
	<b>2023</b>	<p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b>            The Finnish Foundation for Cardiovascular Research</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            Stereotaxis : Arrhythmias, General            Biosense Webster : Arrhythmias, General            Pfizer / BMS Alliance : Pharmacology and Pharmacotherapy</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b>            Biosense Webster : Investigator initiated international multicenter study (MANTRA-VT), Principal Investigator</p>
Refaat Marwan	<b>2022</b>	Nothing to be declared
	<b>2023</b>	Nothing to be declared
Rega Filip	<b>2022</b>	<p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            XVIVO : Heart preservation prior to transplantation, PI</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Rega Filip	<p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b> XVIVO</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Atricure : Atrial Fibrillation (AF)</p> <p><b>Research funding from healthcare industry received personally by you or an entity controlled by you.</b> XVIVO</p>
Rocca Bianca	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Aboca SRL : Other</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Bayer AG : study on low dose rivaroxaban, Chief investigator</p> <hr/> <p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b> Cancer UK</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Aboca, SRL : Other</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b> Editorial Board of: Assistant Editor Diabetes and Vascular Disease Research Advisory Board: Pharmadvances. Associate Editor: Cardiovascular Drugs and Therapy, Clinical Pharmacology Editorial Board: Bleeding, Thrombosis, and Vascular Biology Associate Editor. Frontiers in Drug Safety and Regulation Section on Cardiovascular Drug Safety Associate Editor for European Cardiology Review Editorial Board European Journal of Preventive Cardiology Editorial Board Journal of Thrombosis and Thrombolysis Editorial Board International Journal of Cardiology</p>
Rossello Francisco Javier	<p><b>2022</b> Nothing to be declared</p> <hr/> <p><b>2023</b> Nothing to be declared</p>
Rucinski Marcin	<p><b>2022</b></p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> Member of Polish Cardiac Society</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Rucinski Marcin	<p><b>2023</b>     <b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> Member of Polish Cardiac Society</p>
Salzberg Sacha	<p><b>2022</b>     Nothing to be declared</p>
	<p><b>2023</b>     Nothing to be declared</p>
Sammut Mark	<p><b>2022</b>     <b>Travel and meeting support from healthcare industry, independent of the above activities.</b> Boston Scientific : 2 items checked  Pfizer : 5 items checked</p>
	<p><b>2023</b>     <b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b> Boston Scientific : 2 items checked</p>
Sanfins Victor	<p><b>2022</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Microport : Device Therapy  <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Abbott : Device Therapy Medtronic : Device Therapy Biotronik : Device Therapy Microport : Device Therapy</p>
	<p><b>2023</b>     <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Abbott : Device Therapy Medtronic : Device Therapy Biotronik : Device Therapy Microport : Device Therapy</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Scherr Daniel	<p><b>2022</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Boehringer-Ingelheim : Arrhythmias, General  Medtronic : Arrhythmias, General  Pfizer : Arrhythmias, General  Biotronik : Arrhythmias, General  Bayer Healthcare : Arrhythmias, General  Zoll Medical : Arrhythmias, General  Daiichi Sankyo : Atrial Fibrillation (AF)</p> <hr style="border-top: 1px dashed black;"/> <p><b>2023</b>     <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>  Abbott : Arrhythmias, General  Boston Scientific : Arrhythmias, General  Pfizer : Arrhythmias, General  Biotronik : Arrhythmias, General  Biosense Webster : Arrhythmias, General  Zoll Medical : Arrhythmias, General  Daiichi Sankyo : Atrial Fibrillation (AF)</p>
Schulman Sam	<b>2022</b> Nothing to be declared



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Schulman Sam	<p><b>2023</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>  Astra Zeneca : Other  Boehringer-Ingelheim : Other  Sanofi Aventis : Other  Regeneron : Other  Octapharma : Other  Bayer Canada : Other  Hemostasis Reference Laboratory : Other</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b>  Member of the Executive Committee and Council and Treasurer of International Society on Thrombosis and Haemostasis</p>
Shalghanov Tchavdar	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Astra Zeneca : Chronic Heart Failure</p> <hr/> <p><b>2023</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>  Bayer : Atrial Fibrillation (AF)</p>
Simoni Leonard	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Bayer : Atrial Fibrillation (AF)  Novartis : Chronic Heart Failure</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>  Berlin Chemie AG : Acute Coronary Syndromes  Bayer : Risk Factors and Prevention</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Simoni Leonard	<p><b>2023</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Menarini : Chronic Heart Failure</p> <p><b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b> Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS), Acute Coronary Syndromes</p>
Sisakian Hamayak	<p><b>2022</b></p> <p>Nothing to be declared</p> <hr/> <p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b> Yerevan State Medical University</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Ferrer Internacional : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS) Servier : Hypertension</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b> Servier : Hypertension trial, principan investigator</p>
Smajic Elnur	<p><b>2022</b></p> <p>Nothing to be declared</p> <hr/> <p><b>2023</b></p> <p>Nothing to be declared</p>
Sommer Philipp	<p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Boston Scientific : Atrial Fibrillation (AF) Medtronic : Atrial Fibrillation (AF) Abbott Vascular : Atrial Fibrillation (AF) Biosense Webster : Atrial Fibrillation (AF)</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Abbott : Research Fund, Site investigator</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> Member of Scientific Program Committee DGK (German Society of Cardiology)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Sommer Philipp	<p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b> Fresenius Stiftung</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Edwards Lifesciences : Arrhythmias, General Medtronic : Arrhythmias, General Abbott : Atrial Fibrillation (AF) Boston Scientific : Atrial Fibrillation (AF) Biosense Webster : Atrial Fibrillation (AF)</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> Member of DGK, HRS, EHRA, ESC</p>
Svendsen Jesper Hastrup	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Medtronic : Arrhythmias, General</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b> Abbott : Arrhythmias, General</p> <p><b>Direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</b> Education - Author on section i major Danish textbook (Medicinsk Kompendium)</p> <p><b>Employment (including part time) in healthcare industry during the year for which you are declaring.</b> Swiss Re (insurance company) : Consultancy</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> Danish Heart Foundation and Danish Society of Cardiology</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry	
Svendsen Jesper Hastrup	<b>2023</b>	<p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Medtronic : Arrhythmias, General Vital Beats : Device Therapy</p> <p><b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b> Abbott : Arrhythmias, General</p> <p><b>Direct financial interest in healthcare, media, education companies, or in companies related to or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</b> Education - Author on section i major Danish textbook (Medicinsk Kompendium)</p> <p><b>Employment (including part time) in healthcare industry during the year for which you are declaring.</b> Swiss Re (insurance company) : Consultancy</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> Danish Heart Foundation and Danish Society of Cardiology</p>
Sychoy Oleg	<b>2022</b>	Nothing to be declared
	<b>2023</b>	Nothing to be declared
Taborsky Milos	<b>2022</b>	<p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Astra Zeneca : Chronic Heart Failure Novartis : Cross-Modality and Multi-Modality Imaging Topics</p>
	<b>2023</b>	Nothing to be declared
Taleski Jane	<b>2022</b>	Nothing to be declared
	<b>2023</b>	Nothing to be declared

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
ten Berg Jurrien M	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Astra Zeneca : Acute Coronary Syndromes  Daiichi Sankyo : Acute Coronary Syndromes  Ferrer Internacional : Acute Coronary Syndromes  CeleCOR : Acute Coronary Syndromes</p> <hr/> <p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b>  ZonMw (Dutch Government) institutional grant</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>  Astra Zeneca : Acute Coronary Syndromes  Daiichi Sankyo : Acute Coronary Syndromes  CeleCOR : Acute Coronary Syndromes</p> <p><b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b>  CeleCOR : Acute Coronary Syndromes</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b>  Daiichi Sankyo : WOEST-3 RCT, institutional grant, PI</p>
Ten Cate Hugo	<p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Bayer AG : Basic Science  Astra Zeneca : Clinical Skills  Alveron : Clinical Skills  Galapagos : Clinical Skills  Novostia : Clinical Skills</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b>  Shareholder Coagulation Profile, a Maastricht University spinoff diagnostic small company</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Ten Cate Hugo	<p><b>2023</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            Bayer AG : Basic Science            Astra Zeneca : Clinical Skills            Alveron : Clinical Skills            Galapagos : Clinical Skills            Novostia : Clinical Skills</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b>            Shareholder Coagulation Profile, a Maastricht University spinoff diagnostic small company</p>
Vaartjes Ilonca	<p><b>2022</b> Nothing to be declared</p> <p><b>2023</b> Nothing to be declared</p>
Vrints Christiaan Jm	<p><b>2022</b> Nothing to be declared</p> <p><b>2023</b> Nothing to be declared</p>
Witkowski Adam	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Boston Scientific : Device Therapy            Edwards Lifesciences : Device Therapy            Medtronic : Device Therapy</p> <p><b>2023</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            Boston Scientific : Device Therapy            Edwards Lifesciences : Device Therapy            Medtronic : Device Therapy</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Yap Sing-Chien	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Boston Scientific : Atrial Fibrillation (AF)            Acutus : Atrial Fibrillation (AF)            Medtronic : Device Therapy            Biotronik : Device Therapy</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Medtronic : Incidence of ventricular arrhythmias determined by ILR in CTO patients without severe LV dysfunction, Principal investigator</p> <hr/> <p><b>2023</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            Sanofi Aventis : Arrhythmias, General</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            Boston Scientific : Atrial Fibrillation (AF)</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b>            Boston Scientific : Evaluation of POLARx FIT (BETTER-FIT), PI</p>
Zavatta Marco	<p><b>2022</b> Nothing to be declared</p> <hr/> <p><b>2023</b> Nothing to be declared</p>
Zeppenfeld Katja	<p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Biosense Webster : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Biosense Webster : investigator initiated research, PI</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Zeppenfeld Katja	<p><b>2023</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Biosense Webster : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b> Biosense Webster : Investigator initiated research, ventricular arrhythmias, PI</p>
Zupan Igor	<p><b>2022</b></p> <p>Nothing to be declared</p>
	<p><b>2023</b></p> <p>Nothing to be declared</p>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Arbelo Elena	<b>2021</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Biosense Webster : Atrial fibrillation
	<b>2022</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Biosense Webster : Atrial Fibrillation (AF)
	<b>2023</b> <b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b> Marató TV3  <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Bayer : Atrial Fibrillation (AF) Biosense Webster : Atrial Fibrillation (AF)
Baigent Colin	<b>2021</b> <b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Boehringer-Ingelheim : Renal disease
	<b>2022</b> <b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Boehringer Ingelheim : Grant to the University of Oxford for the EMPA-KIDNEY trial, Co-PI
	<b>2023</b> <b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b> UK Medical Research Council  <b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b> Boehringer-Ingelheim : Funding provided for the coordination of the EMPA-KIDNEY trial, Chair of Steering Committee
Borger Michael A	<b>2021</b> <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Cryolife : aortic surgery Abbott : heart valve therapy Edwards Lifesciences : heart valve therapy Medtronic : heart valve therapy

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Borger Michael A	<p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Artivion (formerly CryoLife) : Diseases of the Aorta            Abbott : Valvular Heart Disease            Edwards Lifesciences : Valvular Heart Disease            Medtronic : Valvular Heart Disease</p>
	<p><b>2023</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            Artivion (formerly CryoLife) : Diseases of the Aorta            Abbott : Valvular Heart Disease            Edwards Lifesciences : Valvular Heart Disease            Medtronic : Valvular Heart Disease</p>
Buccheri Sergio	<p><b>2021</b></p> <p>Nothing to be declared</p>
	<p><b>2022</b></p> <p>Nothing to be declared</p>
	<p><b>2023</b></p> <p>Nothing to be declared</p>
Ibanez Borja	<p><b>2021</b></p> <p>Nothing to be declared</p>
	<p><b>2022</b></p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b>            My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomia, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).</p>
	<p><b>2023</b></p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b>            My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomia, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
James Stefan	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Medtronic : Proctorship</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Astra Zeneca : Clinical trial executive committee Bayer : Clinical trial executive committee Elixir : Clinical trial executive committee jansen : Clinical trial executive committee Amgen : Clinical trial steering committee Novo-Nordisk : Clinical trial steering committee</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Astra Zeneca : Clinical trial Amgen : Clinical trial leadership Elixir : Clinical trial leadership</p>
	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Medtronic : Valvular Heart Disease</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Amgen : Executive committee member, Executive committee member Janssen-Cilag : Executive committee member, Executive committee member Astra Zeneca : Study PI , Principal investigator</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> Swedish medical Association, Swedish cardiac society</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
James Stefan	<p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b> Wallenberg foundation, Swedish heart and lung foundation</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Medtronic : Valvular Heart Disease</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b> Elixir : clinical trial, study chair MSD : Clinical trial, trial executive committee Amgen : Executive committee member, Executive committee member Janssen-Cilag : Executive committee member, Executive committee member Astra Zeneca : Study PI , Principal investigator</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> Swedish medical Association, Swedish cardiac society</p>
Kober Lars	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Astra Zeneca : Heart Failure Bayer : Heart Failure Boehringer-Ingelheim : Heart Failure Novartis : Heart Failure Novo-Nordisk : Heart Failure</p> <hr/> <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Astra Zeneca : Chronic Heart Failure Bayer : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Kober Lars	<p><b>2023</b>     <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>  Astra Zeneca : Chronic Heart Failure  Boehringer-Ingelheim : Chronic Heart Failure  Novartis : Chronic Heart Failure  Novo-Nordisk : Chronic Heart Failure</p>
Koskinas Konstantinos	<p><b>2021</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Amgen : Cardiology  Daiichi Sankyo : Cardiology</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Novartis : Cardiology</p>
	<p><b>2022</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Amgen : Risk Factors and Prevention  Daiichi Sankyo : Risk Factors and Prevention  Sanofi Aventis : Risk Factors and Prevention</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p>
	<p><b>2023</b>     <b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>  Amgen : Risk Factors and Prevention  Daiichi Sankyo : Risk Factors and Prevention  Sanofi Aventis : Risk Factors and Prevention</p>
Mcevoy John William	<p><b>2021</b>     Nothing to be declared</p>
	<p><b>2022</b>     Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry	
Mcevoy John William	<b>2023</b>	Nothing to be declared
Mihaylova Borislava	<b>2021</b>	<p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Merck Sharp &amp; Dohme : Anacetrapib            National Institute for Health Research (UK), Health Technology Assessment Programme : Cost-effectiveness of statin therapy            Barts Charity : Digital pathology            National Institute for Health Research : Various clinical studies including economic evaluations</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b>            I am a member of the Editorial Advisory Board of Value in Health (journal). I do not consider this to present any Col.</p>
	<b>2022</b>	<p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Merck Sharp &amp; Dohme : economic analyses alongside a clinical trial, senior health economist            Barts Charity : Research project, principal investigator            National Institute for Health Research (UK), Health Technology Assessment Programme : Research project, principal investigator            Bowel Research UK : research project, principal investigator</p>
	<b>2023</b>	<p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b>            Barts Charity, UK            Bowel Research UK            Cancer Research UK            National Institute for Health and Care Research, UK</p>
Mindham Richard	<b>2021</b>	<p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Imperial College, London : ONCE-OFF Honorarium, 2019, non-recurring, less than GB£900/€1000, passed in full to UK charity, CardiomyopathyUK</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b>            I have a pension and savings held in shares and funds. I do not control which shares are bought and I do not know whether any of them are invested in healthcare organisations as the shares are managed by a fund manager.</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Mindham Richard	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> PASSpaces. <a href="http://passpaces.co.uk/">http://passpaces.co.uk/</a>. PASSpaces tutors young British doctors to help them pass their medical examinations. I "act" as a patient, permitting the trainee to take a patient history. : Training and Education</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b> European Society of Cardiology. Payment of hotel, travel and meals to attend or speak at ESC conferences. : European Society of Cardiology</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> I support the British charity CardiomyopathyUK, <a href="https://www.cardiomyopathy.org.uk/">https://www.cardiomyopathy.org.uk/</a>. I make small financial contributions to support their activities. I support the British charity Pumping Marvellous, <a href="https://pumpingmarvellous.org/">https://pumpingmarvellous.org/</a>. I make no financial contributions to the charity's activities. I am a member of the Coalition for Reducing Bureaucracy in Clinical Trials, <a href="https://bureaucracyincts.eu/">https://bureaucracyincts.eu/</a>. The Coalition is a collection of researchers, clinicians and patients which advocates for the reduction of bureaucracy in clinical trials, chiefly in the EU. I have no financial interest in the Coalition.</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> I have savings and pensions held in shares. The shares are managed by a financial adviser; I do not control the purchase &amp; sale of shares and I do not know whether any shares are in medical companies.</p>
	<p><b>2023</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> NiCE (National Institute for Health &amp; Care Excellence) - UK Government body. Guideline development.. Commences January 2024. : Chronic Heart Failure</p> <p>PASSpaces. <a href="http://passpaces.co.uk/">http://passpaces.co.uk/</a>. PASSpaces tutors young British doctors to help them pass their medical examinations. I "act" as a patient, permitting the trainee to take a patient history. : Training and Education</p> <p><b>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A.</b> European Society of Cardiology. Payment of hotel, travel and meals to attend or speak at ESC conferences. : European Society of Cardiology</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Mindham Richard	<p><b>2023</b></p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> I support the British charity CardiomyopathyUK, <a href="https://www.cardiomyopathy.org.uk/">https://www.cardiomyopathy.org.uk/</a>. I make small financial contributions to support their activities. I support the British charity Pumping Marvellous, <a href="https://pumpingmarvellous.org/">https://pumpingmarvellous.org/</a>. I make no financial contributions to the charity's activities. I am a member of the Coalition for Reducing Bureaucracy in Clinical Trials, <a href="https://bureaucracyincts.eu/">https://bureaucracyincts.eu/</a>. The Coalition is a collection of researchers, clinicians and patients which advocates for the reduction of bureaucracy in clinical trials, chiefly in the EU. I have no financial interest in the Coalition.</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b> I have savings and pensions held in shares. The shares are managed by a financial adviser; I do not control the purchase &amp; sale of shares and I do not know whether any shares are in medical companies.</p>
Neubeck Lis	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Pfizer : Atrial fibrillation</p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> Medical advisor to the Atrial Fibrillation Alliance</p>
	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Pfizer : Atrial Fibrillation (AF),</p>
	<p><b>2023</b></p> <p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b> Burdett Trust for Nursing Chief Scientists Office</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Sanofi Aventis : Risk Factors and Prevention</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b> Daiichi Sankyo : Atrial fibrillation screening, Principal Investigator</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b> Consultant Editor British Journal of Cardiac Nursing</p>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry	
Nielsen Jens Cosedis	<b>2021</b>	Nothing to be declared
	<b>2022</b>	<p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> Have received research funding to my institution for independent research from the Danish Heart Foundation and the Novo Nordisk Foundation.</p>
	<b>2023</b>	Nothing to be declared
Pasquet Agnes A	<b>2021</b>	<p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Daiichi Sankyo : general cardiology Servier : general cardiology Philips : imaging</p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> member of the Belgian Society of Cardiology</p>
	<b>2022</b>	<p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Philips : Echocardiography, Interventional Cardiology Daiichi Sankyo : Hypertension Servier : Other</p>
	<b>2023</b>	<p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Servier : Hypertension</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Servier : Hypertension</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b> Philips : echography, contribution and support</p>
Prescott Eva	<b>2021</b>	Nothing to be declared

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry	
Prescott Eva	<b>2022</b>	Nothing to be declared
	<b>2023</b>	Nothing to be declared
Rakisheva Amina	<b>2021</b>	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Bayer : Atrial Fibrillatuion Novartis : Heart Failure
	<b>2022</b>	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure Roche Diagnostics : Chronic Heart Failure
	<b>2023</b>	<b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure Roche Diagnostics : Chronic Heart Failure
Rocca Bianca	<b>2021</b>	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Bayer AG : CV prevention in COVID pandemics SOBI : platelet growth factor <b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Bayer AG : anticoagulant (rivaroxaban)
	<b>2022</b>	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Aboca SRL : Other <b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Bayer AG : study on low dose rivaroxaban, Chief investigator

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry	
Rocca Bianca	<b>2023</b>	<p><b>Ongoing research funding from public and/or not-for-profit organisations (which started in 2023 or continues in 2023). This information is not mandatory and does not impact one's ability to join an ESC activity</b> Cancer UK</p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b> Aboca, SRL : Other</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations).</b> Editorial Board of: Assistant Editor Diabetes and Vascular Disease Research Advisory Board: Pharmadvances. Associate Editor: Cardiovascular Drugs and Therapy, Clinical Pharmacology Editorial Board: Bleeding, Thrombosis, and Vascular Biology Associate Editor. Frontiers in Drug Safety and Regulation Section on Cardiovascular Drug Safety Associate Editor for European Cardiology Review Editorial Board European Journal of Preventive Cardiology Editorial Board Journal of Thrombosis and Thrombolysis Editorial Board International Journal of Cardiology</p>
Rossello Francisco Javier	<b>2021</b>	Nothing to be declared
	<b>2022</b>	Nothing to be declared
	<b>2023</b>	Nothing to be declared
Vaartjes Ilonca	<b>2021</b>	Nothing to be declared
	<b>2022</b>	Nothing to be declared
	<b>2023</b>	Nothing to be declared
Vrints Christiaan Jm	<b>2021</b>	Nothing to be declared
	<b>2022</b>	Nothing to be declared
	<b>2023</b>	Nothing to be declared
Witkowski Adam	<b>2021</b>	<p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Boston Scientific : coronary stents, IVUS, Accurate aortic valves (TAVI), Watchman (LAO) Medtronic : Evolute aortic valves (TAVI) Edwards Lifesciences : Sapien aortic valves (TAVI)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2023.

Expert	Type of Relationship with Industry
Witkowski Adam	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Boston Scientific : Device Therapy            Edwards Lifesciences : Device Therapy            Medtronic : Device Therapy</p>
	<p><b>2023</b></p> <p><b>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            Boston Scientific : Device Therapy            Edwards Lifesciences : Device Therapy            Medtronic : Device Therapy</p>
Zeppenfeld Katja	<p><b>2021</b></p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Biosense Webster : Research electrophysiology</p>
	<p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Biosense Webster : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Biosense Webster : investigator initiated research, PI</p>
	<p><b>2023</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities.</b>            Biosense Webster : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p> <p><b>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility.</b>            Biosense Webster : Investigator initiated research, ventricular arrhythmias, PI</p>